Professor Michael Friedlander is conjoint Professor of Medicine at The University of New South Wales and Director of Medical Oncologythe study, diagnosis and treatment of cancer at the Prince of Wales Cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs Centre in Sydney. He has appointments at The Royal Hospital for Women and The Prince of Wales Private Hospital and has a busy private practice at Suite 20. For patients requiring systemic chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells, they may be treated in the oncology day centres at all 3 hospitals.
Major Clinical Interests include Gynaecological Cancers, Breast Cancer, Soft Tissuetissue/the material that joins, holds up or surrounds inside body parts such as fat, muscle, ligaments and lining around joints Sarcomas and Germ Cell Tumours.
He has been very active at both a National and International level in the field of Gynaecological Oncology. He was President of the International Society of Gynaecological Oncology (IGCS) from 2004-2006. He is a senior editor of the International Journal of Gynaecological Oncology. He was the founding Chairman of the ANZ Gynaecologythe study of the female reproductive system and related diseases Oncology Group (ANZGOG) and has held this position from 2000-2008 and remains on the ANZGOG executive and is currently the Research Director of ANZGOG.He is the Principle Investigator for ANZGOG in the US GOG as well as an ANZGOG representative to the Gynaecological Cancer Inter-Group (GCIG).
In addition, he has a long standing commitment over the last 30 years and particular expertise in the management of women with breast cancer .He is a member of the ANZBCTG and has been involved in many clinical trialsresearch studies performed to test new treatments, tests or procedures and evaluate their effectiveness on various diseases as well as led research projects on the management of the late effects of treatment and survivorshipthe ongoing care and support people with cancer receive after cancer diagnosis and treatment issues.
Michael Friedlander was instrumental in establishing and setting up the first hereditary cancer clinic in Australia in 1993.He has maintained a strong research interest in hereditary breast and ovarian cancer and has been very involved in clinical trials with PARP inhibitors in patients with BRCA mutations.
He has held numerous grants and has a very active research program and collaborates with investigators in Australia and Internationally. He has published approximately 250 papers.
Location
20 Barker Street, Kingsford Randwick City Council, NSW, Australia
